Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marie-Thérèse Rubio1, Jeanne Galaine2, Christophe Borg3

  • 1Service d'hématologie, CHRU Nancy, Hopital Brabois, et CNRS UMR 7365, Équipe 6, Biopole de L'Université de Lorraine, 54500 Vandœuvre-les-Nancy, France.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same author

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

NEJM evidence·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

Alternative versus matched unrelated donor in adolescents and young adults transplanted for acute myeloid leukemia in first complete remission: A report from the SFGM-TC.

Bone marrow transplantation·2026

Chimeric antigen receptor (CAR)-T cell therapy reprograms T cells to target tumors, showing success in blood cancers and potential for solid tumors. Ongoing research focuses on improving CAR-T cell efficacy and safety by targeting antigens and enhancing tumor site accessibility.

Area of Science:

  • Immunology and Molecular Biology
  • Oncology
  • Biotechnology

Background:

  • Significant advancements in anti-tumor immunotherapy have emerged.
  • Molecular biology and genetic tools enable T cell reprogramming for cancer treatment.
  • Chimeric antigen receptor (CAR)-T cell therapy represents a major breakthrough.

Purpose of the Study:

  • To review the development and applications of CAR-T cell therapy.
  • To discuss challenges and innovative strategies for enhancing CAR-T cell efficacy and safety.
  • To explore the potential of CAR-T cells in treating both hematological malignancies and solid tumors.

Main Methods:

  • Genetic modification of T cells to express chimeric antigen receptors (CARs).
  • Development of different CAR-T cell generations with optimized gene constructs.
Keywords:
ActivationChimeric antigenGenetically modifiedImmune escapeImmunothérapieLymphocyte activationLymphocytesRécepteur chimériqueTumoranti-tumoralegénétiquementimmunitaireimmunotherapylymphocytairelymphocytesmodifiésreceptorÉchappementà l’antigène

Related Experiment Videos

  • Strategies to identify specific tumor antigens and mitigate off-tumor effects.

    • Main Results:

    • CAR-T cells have demonstrated impressive clinical results in relapsed or refractory lymphoid hematological malignancies.
    • Ongoing development shows promise for CAR-T cell applications in solid tumors.
    • Various approaches are being explored to improve CAR-T cell targeting, persistence, and tumor infiltration.

    Conclusions:

    • CAR-T cell therapy is a revolutionary approach with significant clinical success in certain cancers.
    • Addressing challenges like target identification, on-target/off-tumor effects, and tumor accessibility is crucial for broader application.
    • Continued innovation in CAR-T cell technology is expected to improve treatment outcomes, particularly for solid tumors.